{"id":"W1834728684","doi":"10.1111/dom.12582","title":"Frequency of cancer events with saxagliptin in the <scp>SAVOR‐TIMI</scp> 53 trial","year":2015,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Forest Laboratories; Johnson and Johnson; Eisai; Daiichi-Sankyo; Bayer HealthCare; Hadassah Medical Organization; Gilead Sciences; Medtronic; Roche; Merck; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb; Pfizer; American Diabetes Association","keywords":"Saxagliptin; Medicine; TIMI; Internal medicine; Placebo; Myocardial infarction; Randomized controlled trial; Cancer; Adverse effect; Oncology; Metformin; Sitagliptin; Thrombolysis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004264941,0.0005002548,0.001319624,0.0001717171,0.0002708063,0.00104432,0.0003098182,0.00110105,0.002478508],"category_scores_gemma":[0.002974327,0.0001915752,0.002481496,0.0004611817,0.0003252795,0.0005681601,0.0003419493,0.001540552,0.0002435663],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003686355,"about_ca_system_score_gemma":0.0004710614,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004969373,"about_ca_topic_score_gemma":0.001126434,"domain_scores_codex":[0.9979125,0.001432416,0.0001677771,0.0002136356,0.0001718594,0.0001018388],"domain_scores_gemma":[0.9983187,0.0006959984,0.000522263,0.0001662888,0.000107335,0.0001894665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8872982,0.001636999,0.04156383,0.002901838,0.007913972,0.0001325787,0.0001133517,0.001268873,0.00219646,0.0006591355,0.005238859,0.04907587],"study_design_scores_gemma":[0.5146684,0.114977,0.3212529,0.001106183,0.02254038,0.0005928017,0.0002229698,0.006536179,0.002830067,0.00276131,0.01236183,0.000149961],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"commentary","genre_scores_codex":[0.9726081,0.01764716,0.0008825219,0.001007281,0.0003588771,0.0006566985,0.002658924,0.00006021014,0.004120257],"genre_scores_gemma":[0.9900203,0.003657114,0.0005014936,0.0006483377,0.0003562483,0.0006335055,0.002981983,0.00001559135,0.001185441],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.004264941,"threshold_uncertainty_score":0.02255541,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01865172143367886,"score_gpt":0.2511753008881978,"score_spread":0.2325235794545189,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}